← Research library

Advancement from Small Peptide Pharmaceuticals to Orally Active Piperazine-2,5-dion-Based Cyclopeptides

Review of earlier studies · 2023

What was studied
Source-specific experimental population
Main finding
Development-group review connecting small peptides with cyclic peptidomimetics, including AWE18. AWE18 and CP-88 are separate candidates. Review descriptions of oral activity are not independent clinical trials.

Study data at a glance

Participants or experimental model
Source-specific experimental population
Reported results
Development-group review connecting small peptides with cyclic peptidomimetics, including AWE18. AWE18 and CP-88 are separate candidates. Review descriptions of oral activity are not independent clinical trials.
Study limitations and source details

Study limitations

  • Independent replication and full risk-of-bias appraisal remain unresolved.
  • No personalized treatment or safety conclusion follows from this record.

Source details

Review full text retrieved via Europe PMC. Primary compound-specific studies require separate appraisal.

Sources checked

Citation

ReviewFull text available

Vladislav Deigin, Natalia Linkova, Olga Volpina. Advancement from Small Peptide Pharmaceuticals to Orally Active Piperazine-2,5-dion-Based Cyclopeptides International Journal of Molecular Sciences 24(17):13534

Study source ↗ · DOI 10.3390/ijms241713534 · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards